Reinhart Marville Torre advises medtech Theremia on its equity funding round led by Eurazeo and Salica
Our firm advise medtech Theremia on its equity funding round led by Eurazeo and Salica.
The transaction in detail
A multidisciplinary team of the firm is assisting Theremia, a Paris-based medtech company, on all transactional aspects of its €3 million equity funding round led by Eurazeo and Salica and backed by Entrepreneur First and Bpifrance.
Founded in 2024 by Iris Maréchal and Chloé Geoffroy, Theremia uses advanced AI technologies to develop drug derivatives. The company focuses on personalizing care, particularly in neurological disorders, by optimizing treatments for different population subgroups.
The team that assisted Theremia was led by Hadrien Bourrellis, a partner in corporate/M&A and securities law.
Advisors
Reinhart Marville Torre advised Theremia, with:
- Hadrien Bourrellis, partner, and Charlotte Grenouilloux, associate, for corporate/M&A and negotiation aspects
- Pierre Bonamy, partner, for tax aspects
- Muriel Puyau, counsel, for commercial law and intellectual property aspects
Investors’ advisors on the transaction: Taylor Wessing (Paris)
